Michael Chez to Infant
This is a "connection" page, showing publications Michael Chez has written about Infant.
Connection Strength
0.435
-
Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment. Paediatr Drugs. 2009; 11(6):397-406.
Score: 0.075
-
Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007 Jun; 36(6):361-5.
Score: 0.067
-
Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Behav. 2006 Feb; 8(1):267-71.
Score: 0.061
-
Immunizations, immunology, and autism. Semin Pediatr Neurol. 2004 Sep; 11(3):214-7.
Score: 0.056
-
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program. Epilepsia. 2023 08; 64(8):e156-e163.
Score: 0.051
-
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat Commun. 2019 07 12; 10(1):3094.
Score: 0.039
-
Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid. J Child Neurol. 1999 Apr; 14(4):239-42.
Score: 0.038
-
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019 08; 154:13-20.
Score: 0.038
-
Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999 May; 134(5):607-13.
Score: 0.010